NEW YORK – Taiwanese cancer diagnostic firm ACT Genomics said on Monday that it has launched a study in collaboration with the University of California, San Diego Moores Cancer Center that will evaluate gene expression signals associated with the tumor microenvironment that may predict outcome in melanoma patients treated with PD-1 inhibition.
Scientific Publications
Association of combined PD-L1 expression and tumor-infiltrating lymphocytes features with survival and treatment outcomes in patients with metastatic melanoma
In patients with metastatic melanoma, researchers ascertained if the presence and the characteristics of pretreatment CD8+ tumor-infiltrating T lymphocytes (TILs) could be a complementary prognostic or predictive biomarker.
The National Comprehensive Cancer Network distress thermometer as a screening tool for the evaluation of quality of life in uveal melanoma patients
In patients with uveal melanoma, researchers evaluated quality of life (QoL) status through the National Comprehensive Cancer Network (NCCN) distress thermometer as a psycho-oncological screening tool.
Second primary melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoring
In this prospective cohort study, researchers quantified the risk and examined the time of occurrence of second primary melanoma (SPM). In addition, they identified risk factors for SPM and evaluated the usefulness of total body photography (TBP) and digital dermatoscopic documentation (DDD) for SPM detection.